News and Trends 27 Feb 2020 Scientists Connect Brain Cells to Machines Over the Internet An international group of researchers has set up a brain-machine interface between cultured nerve cells and electronic chips linked over the internet, which could lead to the development of AI implants for treating neurological disorders. As described in a study published in Nature Scientific Reports, the team set up a system where cultured rat nerve […] February 27, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2020 EU Project Set up to Fight Alzheimer’s Disease with Lasers A project has launched with a €3.6M grant to treat neurological conditions such as Alzheimer’s and Huntington’s disease by making brain cells controllable with red light. There are currently no treatments approved that can slow the progression of neurodegenerative conditions, including Alzheimer’s and Huntington’s disease. Treatments approved to alleviate the symptoms only help a small […] February 7, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 9 Dec 2019 As Big Pharma Abandons Neuroscience, Can Biotech Provide Answers? With big pharma exiting the neurology space in droves, biotech innovation might be the key to bring about a much-needed shift. At the Bio-Europe conference in Hamburg last month, experts weighed in on the challenges and future of neuroscience. Over the last decade, big pharma has become disillusioned with neuroscience research. Eli Lilly, Amgen, Pfizer, […] December 9, 2019 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 27 Jun 2019 German Biotech Will Target Parkinsonian Disorders with €12M Series A Modag has developed a candidate drug targeting the neurodegenerative disease multiple system atrophy, which it plans to take to the clinic with €12M in Series A funds. Multiple system atrophy is a rare disorder, with similar symptoms to Parkinson’s disease, that is caused by breakdown of neurons in parts of the brain. The German biotech’s […] June 27, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 May 2019 Top 10 Biotechs in Lausanne The Swiss city of Lausanne is perhaps best known as a hub of international sport, but what many outsiders may not realize is that it’s also one of Switzerland’s biggest biotech hubs. Many of the biotechs in the city are connected to the University of Lausanne (UNIL), as well as the renowned Swiss Federal Institute […] May 8, 2019 - 7 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
More News! 25 Mar 2019 Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug The failure of Biogen’s Alzheimer’s disease drug in a phase III trial last week caused BioArctic’s stock price to plummet by 35% on Nasdaq Stockholm. The Swedish company has just begun a phase III trial of its own Alzheimer’s treatment. Last week, Biogen and its pharma collaborator Eisai discontinued the phase III development of an […] March 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 23 Jan 2019 Update: The FDA Green-lights Clinical Trials for Huntington’s Disease Gene Therapy Update (23/01/2019): The FDA has given uniQure regulatory clearance to begin a phase I/II trial of its gene therapy for Huntington’s disease. uniQure is planning to launch the trial in the US in late 2019. Published on 23/01/2018: The EMA has given uniQure’s gene therapy candidate for Huntington’s disease Orphan Medicinal Product Designation, which the […] January 23, 2019 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Startup Scout 14 Dec 2018 This Company is Strengthening Muscles in Neuromuscular Disorders NMD Pharma, our pick of this week, is based in Aarhus, Denmark. The company is flexing its muscles to develop a drug that can treat muscle weakness in orphan neuromuscular disorders such as amyotrophic lateral sclerosis and myasthenia gravis. Mission: To develop drugs to counteract muscle weakness in incurable neuromuscular disorders. Neuromuscular disorders come […] December 14, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2018 Modulating the Microbiome Could Boost Vaccine Performance Dutch scientists have found that altering a patient’s microbiome with antibiotics before a vaccination can boost the body’s resulting immune response against rotavirus infection. Rotavirus causes severe vomiting and diarrhea and largely affects children. Over 200,000 children are killed by the virus each year. The rotavirus vaccine is made of weakened strains of the rotavirus, […] August 9, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2018 Gene Therapy Could Prevent Deadly Brain Disease An international research team used gene therapy to prevent Gaucher disease, a potentially deadly neurodegenerative condition, in mice. The approach could eventually be used to treat human diseases in the womb. A research team from the UK and Singapore showed that a neurodegenerative condition called Gaucher disease, which can be fatal, can be prevented in […] July 17, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jul 2018 Swedish Alzheimer’s Treatment Slows the Disease in Phase II Trial BioArctic, based in Stockholm, has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial tested the antibody in 856 patients with early-stage Alzheimer’s disease with plaques of amyloid-beta protein in their brains, which is considered a common hallmark of the disease. Results taken at […] July 9, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 27 Jun 2018 International Fund Raises €300M for Dementia Research The Dementia Discovery Fund has raised $350M (€300M) to support industrial and academic scientists doing early-stage research to develop new dementia medicines. Launched in 2015, the Dementia Discovery Fund (DDF) is dedicated to investing in early-stage ventures that develop disease-modifying therapeutics for all types of dementia, including Alzheimer’s and Parkinson’s. Yesterday, the DDF completed a […] June 27, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email